Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review
- PMID: 36921489
- PMCID: PMC9998295
- DOI: 10.1016/j.molimm.2023.03.007
Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review
Abstract
Vaccines induce specific long-term immunological memory against pathogens, preventing the worsening of diseases. The COVID-19 health emergency has caused more than 6 million deaths and started a race for vaccine development. Antibody response to COVID-19 vaccines has been investigated primarily in healthcare workers. The heterogeneity of immune responses and the behavior of this response in particular groups were still very little explored. In this review, we discuss whether antibody responses after vaccination are influenced by age, gender, previous SARS-CoV-2 infection, or pre-existing diseases.
Keywords: Antibody response; COVID-19; SARS-CoV-2; Vaccine.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare that there is no conflict of interest.
Similar articles
-
[Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].Mikrobiyol Bul. 2021 Oct;55(4):519-538. doi: 10.5578/mb.20219705. Mikrobiyol Bul. 2021. PMID: 34666653 Turkish.
-
[Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].Mikrobiyol Bul. 2022 Jan;56(1):36-48. doi: 10.5578/mb.20229904. Mikrobiyol Bul. 2022. PMID: 35088958 Turkish.
-
Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.mSphere. 2022 Aug 31;7(4):e0016922. doi: 10.1128/msphere.00169-22. Epub 2022 Jul 5. mSphere. 2022. PMID: 35862798 Free PMC article.
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
-
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs.Ann Rheum Dis. 2021 Apr;80(4):411-412. doi: 10.1136/annrheumdis-2020-219773. Epub 2021 Feb 9. Ann Rheum Dis. 2021. PMID: 33563595 Free PMC article. Review. No abstract available.
Cited by
-
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables.Neurotherapeutics. 2024 Mar;21(2):e00307. doi: 10.1016/j.neurot.2023.e00307. Epub 2023 Dec 19. Neurotherapeutics. 2024. PMID: 38237381 Free PMC article.
-
Longitudinal Follow-Up Study on the Side Effects of COVID-19 Vaccines: A Telephonic Questionnaire Approach.Cureus. 2024 Jun 22;16(6):e62917. doi: 10.7759/cureus.62917. eCollection 2024 Jun. Cureus. 2024. PMID: 39040783 Free PMC article.
-
Timing and sequence of vaccination against COVID-19 and influenza.Lancet Reg Health Eur. 2023 Jul;30:100663. doi: 10.1016/j.lanepe.2023.100663. Epub 2023 May 30. Lancet Reg Health Eur. 2023. PMID: 37274778 Free PMC article. No abstract available.
-
Comparing Antibody Responses to Homologous vs. Heterologous COVID-19 Vaccination: A Cross-Sectional Analysis in an Urban Bangladeshi Population.Vaccines (Basel). 2025 Jan 13;13(1):67. doi: 10.3390/vaccines13010067. Vaccines (Basel). 2025. PMID: 39852846 Free PMC article.
-
Sex-based difference in immune responses and efficacy of the pneumococcal conjugate vaccine.J Leukoc Biol. 2024 Dec 31;117(1):qiae177. doi: 10.1093/jleuko/qiae177. J Leukoc Biol. 2024. PMID: 39141715
References
-
- Anand S., Montez-Rath M.E., Han J., Garcia P., Cadden L., Hunsader P., Morgan C., Kerschmann R., Beyer P., Dittrich M., Block G.A., Chertow G.M., Parsonnet J. SARS-CoV-2 vaccine antibody response and breakthrough infection in patients receiving dialysis. Ann. Intern. Med. 2022;175:371–378. doi: 10.7326/M21-4176. - DOI - PMC - PubMed
-
- Bachelet T., Bourdenx J.P., Martinez C., Mucha S., Martin-Dupont P., Perier V., Pommereau A. Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times. PLoS One. 2021:16. doi: 10.1371/JOURNAL.PONE.0257646. - DOI - PMC - PubMed
-
- Brisotto G., Muraro E., Montico M., Corso C., Evangelista C., Casarotto M., Caffau C., Vettori R., Cozzi M.R., Zanussi S., Turetta M., Ronchese F., Steffan A. IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers. Clin. Chim. Acta. 2021;523:476. doi: 10.1016/J.CCA.2021.10.035. - DOI - PMC - PubMed
-
- Broeders N.E., Hombrouck A., Lemy A., Wissing K.M., Racapé J., Gastaldello K., Massart A., van Gucht S., Weichselbaum L., de Mul A., Brochier B., Thomas I., Abramowicz D. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin. J. Am. Soc. Nephrol. 2011;6:2573–2578. doi: 10.2215/CJN.04670511. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous